Apollo Hospitals (APOHOS) 1337
|
|
- Francine Dennis
- 7 years ago
- Views:
Transcription
1 Result Update Rating matrix Rating : Hold Target : 14 Target Period : 12 months Potential Upside : 4% What s Changed? Target Unchanged EPS FY16E Changed from 35.3 to 3.9 EPS FY17E Changed from 43.4 to 41. Rating Changed from Buy to Hold Standalone Quarterly Performance Q1FY16 Q1FY15 YoY (%) Q4FY15 QoQ (%) Revenue 1,265. 1, , EBITDA EBITDA (%) bps bps Net Profit Key Financials ( Crore) FY14 FY15 FY16E FY17E Revenues EBITDA Net Profit EPS ( ) Valuation summary FY14 FY15 FY16E FY17E PE (x) EV to EBITDA (x) Target EV/EBITDA (x) Price to book (x) RoNW (%) RoCE (%) Stock data Particular Amount Market Capitalisation crore Debt (FY15) 422 crore Cash (FY15) 377 crore EV crore 52 week H/L 148/122 Equity capital 69.6 crore Face value 5 Price performance (%) 1M 3M 6M 1Y Apollo Hospitals Fortis Healthcare Research Analyst Siddhant Khandekar siddhant.khandekar@icicisecurities.com Mitesh Shah mitesh.sha@icicisecurities.com Nandan Kamat nandan.kamat@icicisecurities.com August 14, 215 Apollo Hospitals (APOHOS) 1337 Margin improvement; work in progress Revenues increased 2% YoY to 1265 crore (I-direct estimate of 1316 crore) on the back of 34.7% YoY increase in pharmacy business to 52.1 crore (I-direct estimate: 55.7 crore). The healthcare business grew 11.6% to 745 crore (I-direct estimate: crore) to 745 crore EBITDA margins declined only 52 bps to 14.3% (I-direct estimate: 14.2%) on account of lower-than-expected other expenditure. EBITDA increased 15.8% YoY to crore Net profit rose 9.8% to 9.8 crore (I-direct estimates: 98.6 crore) Healthcare business growth to piggyback on sustained expansion The healthcare services segment (54% of consolidated revenues) has grown at a CAGR of ~16% in FY1-15 on account of incremental hospital addition in all three clusters i.e. Chennai, Hyderabad and others. Rapid expansion and maturity of older hospitals have kept the overall growth tempo over and above 15% per annum. The next phase of expansion includes addition of 135 beds to the existing network of 4 hospitals and 7123 beds (own hospitals) by FY19 with an additional capex of 1477 crore. This is likely to put some pressure on EBITDA margins in the short to medium term. However, in the past, the company has demonstrated its ability to balance between expansion and margins. By acquiring Nova speciality and Assam Hospitals, the company has also opted for the inorganic route for expansion. We expect more focus in improvement of important parameters such as average length of stay (ALOS) and average revenue per operating bed (AROPB) that have been flat in the last few quarters on account of incremental bed additions. We expect healthcare sales to grow at a CAGR of 12.4% in FY15-17E to 47.7 crore as the company keeps on investing in new assets. Pharmacy business EBITDA positive; candidate for value unlocking The pharmacy business (34% of consolidated revenues) has grown at a CAGR of ~3% over the last five years on the back of consistent addition of new pharmacies and timely closure of non-performing pharmacies. This business has become EBITDA positive as old stores are maturing and making a contribution. We expect the pharmacy business to grow at a CAGR of 13.7% in FY15-17E to 265 crore on the back of higher sales from existing stores. The company has added 45 stores in Q1FY16 along with consolidation of 34 Hetero stores taking total stores to In the last three years, we have seen a strong improvement in revenues per store from 15 lakh in FY11 to 27 lakh in FY15. The Hetero acquisition may put some pressure on margins initially but augurs well in the long run for scalability. Profitability of new hospitals key for overall margin improvement We expect consolidated sales, EBITDA and PAT to grow at a CAGR of 12.4%, 17% and 2%, respectively, in FY15-17E. The newly commissioned hospitals have achieved the break even (BE) level fairly ahead of our expectations. The focus will now shift to operational gauges for different cluster hospitals as the current phase of capex cycle nears the end. The Nova and Assam acquisition have demonstrated Apollo s willingness to opt for the inorganic route for expansion through localised targets with good capability. On the other hand, pharmacy margins that showed an improvement recently may take a hit in the medium term on the back of the Hetero stores acquisition. Our revised target price is 14 as per SOTP valuation. ICICI Securities Ltd Retail Equity Research
2 Variance analysis Q1FY16 Q1FY16E Q1FY15 Q4FY15 YoY (%) QoQ (%) Comments Revenue 1,265. 1,316. 1,53.7 1, Growth driven by ~34.7% growth in pharmacy segment Raw Material Expenses Employee Expenses Other expenditure EBITDA EBITDA (%) bps -18 bps The decline in margins was mainly due to higher growth in the low margin pharmacy business and lower margins fetched by newly commissioned hospitals. The pharmacy business margins were 3.6% while healthcare services margins were 24% Interest Higher financial cost was mainly due to higher leverage for new facilities commissioned in Q4FY15 Depreciation Other Income PBT before EO & Forex EO PBT after Exceptional Items Tax Tax rate (%) Net Profit YoY growth was lower vis-à-vis EBITDA due to higher financial cost EPS ( ) Key Metrics Healthcare Services Growth mainly driven by new hospital additions Pharmacy Growth driven by integration of Hetero pharmacy, 45 net stores addition and traction from mature stores. Excluding Hetero, revenue growth was 31% Change in estimates FY16E FY17E ( Crore) Old New % Change Old New % Change Comments Revenue 6,43.1 6, , , EBITDA 1, , , EBITDA Margin (%) bps bps Reduced margin expectation due to slower-than-expected margin improvement at new facilities PAT EPS ( ) Assumptions Current Earlier (% Growth) FY14 FY15 FY16E FY17E FY16E FY17E Healthcare Services 2, ,82.7 3, ,7.7 3, ,11.6 Pharmacy 1, , , ,64.9 2, ,663.8 Subsidiaries & consulting fees JVs ICICI Securities Ltd Retail Equity Research Page 2
3 Company Analysis Established in 1983, the company is one of the few listed players in the healthcare space. It derives revenues from two broader segments in standalone accounts - 1) Healthcare services i.e. hospitals & 2) standalone pharmacies. In consolidated accounts, other reporting segments are 1) hospital revenues from JVs/subsidiaries & associates, 2) Apollo-Munich Health insurance JV, 3) ApolloHealth & Lifestyle Ltd, which is the retail healthcare business of Apollo Hospitals. Apollo owns 64 hospitals with a total bed capacity of 8985 beds. Of these 64 hospitals, 4 are owned by the company (including JVs, subsidiaries and associates) while eight are managed by the company with 1434 beds and 16 are day care/short surgical stay centres and cradles with 428 beds. This business has been categorised as the healthcare business and comprises ~61% of standalone revenues. In case of managed hospitals, the company charges 5-6% management fees to third-party hospitals for project management and consultancy covering all facets of development and operation of a hospital, including market research, technical design, arranging finance, hiring manpower and running the facility. The healthcare segment has been divided into three clusters- 1) Chennai, 2) Hyderabad and 3) others, which includes hospitals in Madurai, Karur, Karaikudi, Trichy, Mysore, Vizag, Pune, Karimnagar, Bilaspur, Bhubaneswar and Jayanagar. In case of standalone pharmacies, that are basically drug stores chain selling prescription, OTC and private label FMCG products, the company owns 2171 stores. Overall, we expect revenues to grow at a CAGR of 12.4% in FY15-17E to crore. Exhibit 1: Revenues to grow at CAGR of 12.4% in FY15-17E FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E Revenues The healthcare services segment (54% of consolidated revenues) has grown at ~16% CAGR in FY1-15 on account of incremental hospital addition in all three clusters i.e. Chennai, Hyderabad and others. Rapid expansion and maturity of older hospitals have kept overall growth tempo over and above 15% per annum. The next phase of expansion includes addition of 135 beds to the existing network of 4 hospitals and 7123 beds (own hospitals) by FY19 with an additional capex of 1477 crore. ICICI Securities Ltd Retail Equity Research Page 3
4 This is likely to put some pressure on EBITDA margins in the short to medium term. However, in the past, the company has demonstrated its ability to balance between expansion and margins. By acquiring Nova Speciality and Assam Hospitals, the company has also opted for the inorganic route for expansion. We expect more focus in improvement of important parameters such as average length of stay (ALOS) and average revenue per operating bed (AROPB), which were flat in the last few quarters on account of incremental bed additions. We expect healthcare sales to grow at 12.4% CAGR in FY15-17E to 47.7 crore as the company keeps on investing in new assets. Exhibit 2: Healthcare services to grow at CAGR of 12.4% in FY15-17E FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E Healthcare Services The pharmacy business (34% of consolidated revenues) has grown at a CAGR of ~3% in the last five years on the back of consistent addition of new pharmacies and timely closure of non-performing pharmacies. This business has become EBITDA positive as more and more old stores are maturing and making contribution. We expect the pharmacy business to grow at a CAGR of 13.7% in FY15-17E to crore on the back of higher sales from existing stores. The company has added 45 stores along with consolidation of 34 Hetero stores in Q1FY16 taking total stores to In the last three years, we have seen a strong improvement in revenue per store from 15 lakh in FY11 to 27 lakh in FY15. The pharmacy business is also a candidate for possible value unlocking. Exhibit 3: Pharmacy business to grow at CAGR of 13.7% in FY15-17E FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E Pharmacy ICICI Securities Ltd Retail Equity Research Page 4
5 Exhibit 4: Subsidiaries & others to grow at CAGR of 7.1% in FY15-17E FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E Subsidiaries & consulting fees Source: Company, ICICIdirect.com, Research Exhibit 5: JVs sales to grow at CAGR of 9.3% in FY15-17E FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E Add JV Source: Company, ICICIdirect.com, Research Exhibit 6: EBITDA to grow at CAGR of 17% in FY15-17E (%) FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E EBITDA EBITDA Margins (%) 12 Exhibit 7: Net profit to grow at CAGR of 2% in FY15-17E (%) FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E Net Profit Net Profit Margins (%) ICICI Securities Ltd Retail Equity Research Page 5
6 Exhibit 8: Trends in return ratios (%) FY9 FY1 FY11 FY12 FY13 FY14 FY15 FY16E FY17E RoCE (%) RoNW (%) ICICI Securities Ltd Retail Equity Research Page 6
7 Exhibit 9: Trends in Standalone quarterly financials Q2FY13 Q3FY13 Q4FY13 Q1FY14 Q2FY14 Q3FY14 Q4FY14 Q1FY15 Q2FY15 Q3FY15 Q4FY15 Q1FY16 YoY (%) QoQ (%) Total Operating Income Raw Material Expenses as % revenues Gross Profit GPM (%) Employee Expenses as % revenues Marketing Expenses as % revenues Other expenditure as % revenues Total expenditure EBITDA EBITDA Margins (%) bps -18 bps Depreciation Interest Other Income PBT Less: Exceptional Items Total Tax Tax rate (%) Net Profit Net Profit Margin (%) EPS (Adjusted) Exhibit 1: Standalone healthcare service performance ( Crore) Q2FY13 Q3FY13 Q4FY13 Q1FY14 Q2FY14 Q3FY14 Q4FY14 Q1FY15 Q2FY15 Q3FY15 Q4FY15 Q1FY16 YoY (%) QoQ (%) Sales EBITDA EBITDA Margins (%) Exhibit 11: Standalone pharmacy performance Q2FY13 Q3FY13 Q4FY13 Q1FY14 Q2FY14 Q3FY14 Q4FY14 Q1FY15 Q2FY15 Q2FY15 Q3FY15 Q4FY15 YoY (%) QoQ (%) Sales EBITDA EBITDA Margins (%) No of Stores Rev per store ( lakh) SWOT Analysis Strengths - Early mover in healthcare space. Strong balance sheet despite being in a business of higher gestation period. Strong brand value, a significant aspect in this business Weakness- Presence in low margin pharmacy space Opportunities - Under-penetrated Indian healthcare space with favourable demographics and disease pattern Threats - Too much capacity build-up may lead to lower capacity utilisation and cost associated with it ICICI Securities Ltd Retail Equity Research Page 7
8 Conference call highlights The company plans to add 8 new beds in Navi Mumbai, Malleshwaram and Vizag by the end of FY16 Net pharmacy store addition in Q1FY16 was 45 stores with integration of 34 Hetero stores taking total stores to 2171 Apollo expects Hetero stores to be profitable by end of FY16 It plans to add 875 beds by FY16 North Bangalore 18, Chennai Main 3, Navi Mumbai 35, Indore 65 and Vizag 25. Out of total bed addition in FY16, ~78 are expected to be added from its three new hospitals in Navi Mumbai, Malleshwaram and Vizag In FY17, facilities in Navi Mumbai and Bangalore are expected to get commissioned with 885 beds It plans to add another 475 beds in FY19 - South Chennai 175, South Mumbai 3 Estimated capex for this expansion is ~ 1,477 crore, of which it has already spent 64 crore. The remaining balance amount may be funded through a mix of internal accruals and proposed rights Issue. Majority of the capex would be done in FY16 Two hospitals at Vanagaram and Jayanagar (added in the last 24 months) have more than 5% occupancies. Hospitals at Trichi, Nashik and Nellore are expected to reach 4-5% occupancy by end of FY16 The acquired hospital in Guwahati is generating revenues of 8-1 crore and is profitable. The company plans to increase the capacity from 2 beds to 3 beds in the next three to four years The company expects 25% EBITDA margins from the healthcare segment while pharmacy margins are expected to improve to 6% in the next two to three years The company expects a spike in expenditure on account of higher advertising and marketing costs from Q2FY16 Apollo plans to enhance Hyderabad occupancy levels to 65-7% from 6% over the next few quarters ICICI Securities Ltd Retail Equity Research Page 8
9 Valuation We expect consolidated sales, EBITDA and PAT to grow at a CAGR of 12.4%, 17% and 2%, respectively, in FY15-17E. The newly commissioned hospitals have achieved the break even (BE) level fairly ahead of our expectations. The focus will now shift to operational gauges for different cluster hospitals as the current phase of capex cycle nears its end. The Nova and Assam acquisition have demonstrated Apollo s willingness to opt for the inorganic route for expansion through localised targets with good capability. On the other hand, pharmacy margins that showed an improvement recently may take some hit in the medium-term on the back of Hetero stores acquisition. Our revised target price stands at 14 as per SOTP valuation. Exhibit 12: One year forward EV/EBITDA Mar-6 Sep-6 Mar-7 Sep-7 Mar-8 Sep-8 Mar-9 Sep-9 Mar-1 Sep-1 Mar-11 Sep-11 Mar-12 Sep-12 Mar-13 Sep-13 Mar-14 Sep-14 Mar-15 [ EV 18.9x 18.1x 16.5x 14.1x 12.5x Exhibit 13: Valuation Particulers Valuation Matrix Multiple (x) Enterprise value ( cr) Healthcare EV/EBITDA ,351 Pharmacy EV/Sales 1.5 3,97 Others EV/Sales Cash 197 Expected Net Debt ( cr) 1,692 EV 19,497 No of shares (cr) 13.9 Per Share Value 1,41 Exhibit 14: Valuation Revenues Growth EPS Growth P/E EV/EBITDA RoNW RoCE (%) ( ) (%) (x) (X) (%) (%) FY FY FY16E FY17E ICICI Securities Ltd Retail Equity Research Page 9
10 Company snapshot 1,6 1,4 Target Price: 14 1,2 1, Jan-9 Apr-9 Jul-9 Oct-9 Jan-1 Apr-1 Jul-1 Oct-1 Jan-11 Apr-11 Jul-11 Oct-11 Jan-12 Apr-12 Jul-12 Oct-12 Jan-13 Apr-13 Jul-13 Oct-13 Jan-14 Apr-14 Jul-14 Oct-14 Jan-15 Apr-15 Jul-15 Oct-15 Jan-16 Apr-16 Jul-16 Source: Bloomberg, Company, ICICIdirect.com Research Key events Date Sep-8 Jun-9 Event Opens first reach hospital at Karimnagar, Andhra Pradesh Issues 15 unsecured foreign currency convertible bonds of US$1 each to International Finance Corporation aggregating to US$15 million. IFC also granted a loan May-11 Pharmacy business of company turns profitable for first time Sep-12 Government allows foreign direct investment in multi brand retail. Pharmacy business of Apollo Hospitals falls into this category Dec-12 Sells stake in its BPO company Apollo Health Street to US based company Sutherland Global Services. It holds 39.4% in Apollo Health Street Jan-13 Plans to establish a proton therapy centre in India. It will be first of its kind across South East Asia, Africa and Australia. May-13 Apollo Hospitals and Yash Birla Group call off their JV & shut down their plans to set up super specialty hospitals in Thane, Mumbai Sep-14 Enters into agreement to acquire 32 pharmacy stores from Hetero for 146 crore Jan-15 Acquires Bengaluru-based Nova Specialty Hospitals at an estimated cost of crore Top 1 Shareholders Rank Name Latest Filing Date % O/S Position (m) Position Chan 1 PCR Investments, Ltd. 3-Jun Integrated Mauritius Healthcare Holdings, Ltd. 3-Jun OppenheimerFunds, Inc. 3-Jun Reddy (Prathap C) 3-Jun Fidelity Management & Research Company 3-Jun Newton Investment Management Ltd. 3-Jun Reddy (Suneeta) 3-Jun Schroder Investment Management Ltd. (SIM) 3-Jun Reddy (Sangita) 3-Jun MEAG Munich ERGO Kapitalanlagegesellschaft mbh 3-Jun Source: Reuters, ICICIdirect.com Research Shareholding Pattern (in %) Jun-14 Sep-14 Dec-14 Mar-15 Jun-15 Promoter FII DII Others Recent Activity Buys Sells Investor name Value Shares Investor name Value Shares Newton Investment Management Ltd m 3.59m Fidelity Management & Research Company -2.17m -.97m Mirae Asset Global Investments (Hong Kong) Limited 14.51m.7m Life Insurance Corporation of India m -.66m OppenheimerFunds, Inc. 8.43m.41m Schroder Investment Management (Singapore) Ltd. -4.3m -.23m Reddy (Karthik Anand) 6.39m.33m Capital Investment Trust Corporation -3.59m -.2m Reddy (Harshad) 6.19m.32m Sydinvest -3.11m -.2m Source: Reuters, ICICIdirect.com Research ICICI Securities Ltd Retail Equity Research Page 1
11 Financial summary Profit and loss statement Crore (Year-end March) FY14 FY15 FY16E FY17E Revenues 4, , ,261. 7,346.3 Growth (%) Raw Material Expenses 2,15.1 2, , ,82.1 Employee Expenses ,124. Marketing Expenses Other expenditure Total Operating Expenditure 3, , , ,169.7 EBITDA ,176.7 Growth (%) Depreciation Interest Other Income PBT Total Tax MI & Profit from Associates Adjusted PAT Growth (%) EPS (Adjusted) Cash flow statement Crore (Year-end March) FY14 FY15 FY16E FY17E Profit/(Loss) after taxation Add: Depreciation & Amortization Working Capital Changes CF from operating activities Change in Capex (Inc)/dec in Investments (Increase)/Decrease in Long term Other investing activities CF from investing activities Issue of Equity Inc/(dec) in loan funds Dividend paid & dividend tax Other financing activities CF from financing activities Net Cash flow Opening Cash Closing Cash Balance sheet Crore (Year-end March) FY14 FY15 FY16E FY17E Equity Capital Reserve and Surplus 2,97.1 3,1.6 3,48.7 3,817.6 Total Shareholders funds 2, ,17.2 3, ,887.2 Total Debt 1, , , ,692.3 Deferred Tax Liability Minority Interest Long term provisions Other Non Current Liabilities Total Liabilities 4, , , ,144.3 Gross Block - Fixed Assets 3, ,43.5 4,83.4 5,453.4 Accumulated Depreciation ,1.7 1, ,511.3 Net Block 2, ,32.8 3,56.4 3,942.2 Capital WIP Net Intangible assets Goodwill on Consolidation Total Fixed Assets 3, , , ,33.5 Investments Inventory Debtors Loans & Advances, & other CA Cash Total Current Assets 1, , ,94.6 2,11.4 Creditors Provisions & Other CL Total Current Liabilities Net Current Assets , ,292.6 Long term loans & advances Deferred Tax Assets Application of Funds 4, , , ,144.3 Key ratios (Year-end March) FY14 FY15 FY16E FY17E Per share data ( ) Adjusted EPS Cash EPS BV per share Dividend per share Cash Per Share Revenue per Share Operating Ratios (%) EBITDA margins Net Profit margins Inventory days Debtor days Creditor days Return Ratios (%) RoE RoCE RoIC Valuation Ratios (x) P/E EV / EBITDA EV / Net Sales Market Cap / Sales Price to Book Value Solvency Ratios Debt / EBITDA Debt / Equity Current Ratio Quick Ratio Quick Ratio ICICI Securities Ltd Retail Equity Research Page 11
12 ICICIdirect.com coverage universe (Healthcare) I-Direct CMP TP Rating M Cap EPS ( ) PE(x) EV/EBITDA (x) RoCE (%) RoNW (%) Company Code ( ) ( ) ( Cr) FY15 FY16E FY17E FY15 FY16E FY17E FY15 FY16E FY17E FY15 FY16E FY17E FY15 FY16E FY17E Ajanta Pharma AJAPHA BUY Apollo Hospitals APOHOS HOLD Aurobindo Pharma AURPHA BUY Biocon BIOCON HOLD Cadila Healthcare CADHEA BUY Cipla CIPLA HOLD Dr Reddy's Labs DRREDD BUY Glenmark Pharma GLEPHA HOLD Indoco Remedies INDREM BUY Ipca Laboratories IPCLAB HOLD Jubilant Life Sciences VAMORG HOLD Lupin LUPIN BUY Natco Pharma NATPHA HOLD Sun Pharma SUNPHA HOLD Torrent Pharma TORPHA BUY Unichem Laboratories UNILAB HOLD ICICI Securities Ltd Retail Equity Research Page 12
13 RATING RATIONALE ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock. Strong Buy: >15%/2% for large caps/midcaps, respectively, with high conviction; Buy: >1%/15% for large caps/midcaps, respectively; Hold: Up to +/-1%; Sell: -1% or more; Pankaj Pandey Head Research pankaj.pandey@icicisecurities.com ICICIdirect.com Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai 4 93 research@icicidirect.com ICICI Securities Ltd Retail Equity Research Page 13
14 ANALYST CERTIFICATION We /I, Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Nandan Kamat MBA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & conditions and other disclosures: ICICI Securities Limited is a Sebi registered Research Analyst having registration no. INH99. ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India s largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ( associates ), the details in respect of which are available on ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any material conflict of interest at the time of publication of this report. It is confirmed that Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Nandan Kamat MBA, Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. It is confirmed that Siddhant Khandekar, CA INTER and Mitesh Shah, MS (finance), Nandan Kamat MBA, Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report. ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report. We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. ICICI Securities Ltd Retail Equity Research Page 14
Apollo Hospitals (APOHOS) 1446
Result Update Rating matrix Rating : Hold Target : 142 Target Period : 15-18 months Potential Upside : -2% What s Changed? Target Changed from 134 to 142 EPS FY16E Changed from 29.1 to 28. EPS FY17E Changed
More informationApollo Hospitals (APOHOS) 1344
Result Update Rating matrix Rating : Hold Target : 142 Target Period : 15-18 months Potential Upside : 6% What s Changed? Target Unchanged EPS FY16P Changed from 23.9 to 22.2 EPS FY17E Changed from 34.6
More informationGraphite Electrodes. Imposition of antidumping duty augurs well. Sector Update. ICICI Securities Ltd Retail Equity Research.
Sector Update Rating matrix Target price Company Old New CMP Potential Upside HEG 225 275 238 19% Graphite India 85 15 91 18% Target period 12-15 months Price performance (%) Return % 1M 3M 6M 12M HEG
More informationNatco Pharma (NATPHA)
Result Update Rating matrix Rating : Hold Target : 378 Target Period : 12 months Potential Upside : 5% Key Financials ( crore) FY11 FY12 FY13E FY14E Revenues 444.9 518.5 635. 727.5 EBITDA 86.8 115.5 14.7
More informationQuant Picks United Breweries
October 6, 2015 Quant Picks United Breweries Research Analyst Amit Gupta amit.gup@icicisecurities.com Raj Deepak Singh rajdeepak.singh@icicisecurities.com Azeem Ahmad azeem.ahmad@icicisecurities.com i
More informationEast India Hotels (EIH) 114
Result Update Rating matrix Rating : Hold Target : 124 Target Period : 12-15 months Potential Upside : 8% What s Changed? Target Changed from 133 to 124 EPS FY16E Unchanged EPS FY17E Changed from 2.8 to
More informationGujarat State Petronet Ltd. INR 135
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Oil & Gas RESULT UPDATE Gujarat State Petronet Ltd. INR 135 Growth in volumes to propel earnings Accumulate Gujarat
More informationResearch Analysts. April 8, 2016. West Coast Paper Mills WESCOA Buy in the range of 75-78 96.00 68.00
Stocks on the move Scrip IDi I-Direct tcode Action Target Stoploss West Coast Paper Mills WESCOA Buy in the range of 75-78 96.00 68.00 Time Frame: 3 Months Research Analysts Dharmesh Shah dharmesh.shah@icicisecurities.com
More informationButterfly Gandhimathi (GANAP) 188
Result Update Rating matrix Rating : Buy Target : 240 Target Period : 12 months Potential Upside : 27% What s changed? Target EPS FY16E EPS FY17E Rating Quarterly performance Unchanged Unchanged Unchanged
More informationResearch Analysts. September 30, 2015
Stocks on the move Scrip I-Direct Code Action Target Stoploss Hitachi Home and Life Solutions AMTAPP Buy in the range of 1380.00-1400.00 1640.00 1280.00 Time Frame: 3 Months Research Analysts Dharmesh
More informationEast India Hotels (EIH) 109
Result Update Rating matrix Rating : Hold Target : 1 Target Period : 12-15 months Potential Upside : -8% What s Changed? Target Changed from 124 to 1 EPS FY17E Changed from 2.3 to 2. EPS FY18E Introduced
More informationGladiator Stocks: Phillips Carbon Black (PHICAR) Time Frame: Six months
Gladiator Stocks: Phillips Carbon Black (PHICAR) Time Frame: Six months CMP: 160.00 00 Buying Range: 155.00-160.00 160 Target: 196.00 Stop loss: 137.00 Upside: 25% Stock Data 52 Week High / Low 162.95/80
More informationResearch Analysts. Granules GRANUL Buy in the range of 142.00-146.00 168.00 133.00 EID Parry EIDPAR Buy in the range of 128.00-134.00 170.00 121.
Stocks on the move Scrip IDi I-Direct Code Action Target Stoploss Granules GRANUL Buy in the range of 142.00-146.00 168.00 133.00 EID Parry EIDPAR Buy in the range of 128.00-134.00 170.00 121.00 Time Frame:
More informationResearch Analysts. June 30, 2016. Lupin LUPIN Buy in the range of 1520.00-1550.00 1770.00 1388.00
Stocks on the move Scrip IDi I-Direct tcode Action Target Stoploss Lupin LUPIN Buy in the range of 1520.00-1550.00 1770.00 1388.00 Time Frame: 3 Months Research Analysts Dharmesh Shah dharmesh.shah@icicisecurities.com
More informationHEG Ltd (HEG) 160. Performs well. Result Update. ICICI Securities Ltd Retail Equity Research. November 10, 2015
Result Update Rating matrix Rating : Hold Target : 175 Target Period : 12 months Potential Upside : 9% What s Changed? Target Changed from 185 to 175 EPS FY16E Unchanged from 9.1 to 9.5 EPS FY17E Unchanged
More informationBharti Infratel (BHAINF) 370
Result Update Rating matrix Rating : Buy Target : 500 Target Period : 12 months Potential Upside : 35% What s changed? Target Changed from 530 to 500 EPS FY16E Changed from 12.1 to 12 EPS FY17E Changed
More informationGAIL (India) Ltd. INR 346
Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 India Equity Institutional Research Oil & Gas RESULT UPDATE GAIL (India) Ltd. INR 346 Good performance; Near term outlook looks stable BUY GAIL reported
More informationSAIL (SAIL) 56. Dismal performance. Result Update. ICICI Securities Ltd Retail Equity Research. August 17, 2015
Result Update Rating matrix Rating : Sell Target : 50 Target Period : 12 months Potential Upside : -11% What s Changed? Target Changed from 60 to 50 EPS FY16E Changed from 4.8 to 1.1 EPS FY17E Changed
More informationMinda Industries Ltd. INR 886
Jan-15 Mar-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 India Equity Institutional Research Automobiles RESULT UPDATE Minda Industries Ltd. INR 886 Profit boosted by margins ACCUMULATE In Q3FY16, Minda Industries
More informationIdea Cellular (IDECEL) 178
Result Update Rating matrix Rating : Buy Target : 215 Target Period : 12 months Potential Upside : 24% What s changed? Target Unchanged EPS FY16E Changed from 9.3 to 10.1 EPS FY17E Changed from 6.1 to
More informationKhambatta Securities Ltd.
Attractive Valuation Strong Buy Sector : Bank Private Target Price : Rs 284 Current Market Price : Rs 230 Market Cap : Rs 1,337 bn 52-week High/Low : Rs 393/216 Daily Avg. Volume : 13.88 mn Shares in issue
More informationHCC BUY. Infrastructure January 29, 2016
Jan-15 Mar-15 Apr-15 May-15 Jul-15 Aug-15 Sep-15 Nov-15 Dec-15 Jan-16 India Research Infrastructure January 29, 2016 QUARTERLY REVIEW Bloomberg: IN Reuters: HCNS.BO BUY Better margins drive earnings s
More informationCoal India (COALIN) 318
Result Update February 16, 2016 Rating matrix Rating : Buy Target : 375 Target Period : 12 months Potential Upside : 18% What's Changed? Target Changed from 400 to 375 EPS FY16E Unchanged from 23.0 to
More informationFirstsource Solutions (FIRSOU) 31
Result Update Rating matrix Rating : Buy Target : 45 Target Period : 12 months Potential Upside : 45% What s changed? Target EPS FY16E EPS FY17E Rating Unchanged Unchanged Unchanged Unchanged Quarterly
More informationJindal Saw (SAWPIP) 64
Result Update November 20, 2015 Rating matrix Rating : Hold Target : 60 Target Period : 12 months Potential Upside : -6% What s Changed? Target Changed from 85 to 60 EPS FY16E Changed from 13.2 to 12.7
More informationAban Offshore (ABALLO) 180
Result Update Rating matrix Rating : Sell Target : 145 Target Period : 12 months Potential Upside : -19% What s changed? Target Changed from 223 to 145 EPS FY16E Changed from 73.1 to 9.7 EPS FY17E Changed
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 SPS Finquest Ltd CMP: 84.60 January 13, 2015 Stock Details BSE code 538402 BSE ID SPS Face value ( ) 10 No of shares
More informationWipro Ltd (Wipro) 567
Result Update Rating matrix Rating : Buy Target : 680 Target Period : 12 months Potential Upside : 20% What s Changed? Target EPS FY16E EPS FY17E Rating Unchanged Unchanged Unchanged Unchanged Quarterly
More informationPitti Laminations (PITLAM) 48
Result Update Rating matrix Rating : Hold Target : 5 Target Period : 12-18 months Potential Upside : 4% What s changed? Target Changed form 78 to 5 EPS FY16E Profit to Loss EPS FY17E Changed from 5.6 to
More informationFlexituff International Ltd. (FIL)
s $CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 (Wholly owned subsidiary of Bank of Baroda) Q2FY16 Result Review BUY Flexituff International Ltd. (FIL)
More informationAmara Raja Batteries (AMARAJ) 870
Result Update Rating matrix Rating : Hold Target : 925 Target Period : 12 months Potential Upside : 6% What s Changed? Target Changed from 1000 to 925 EPS FY16E Changed from 29.8 to 30.2 EPS FY17E Changed
More informationKotak Mahindra Bank Rs 685
India Equity Institutional Research BANKS RESULT UPDATE Kotak Mahindra Bank Rs 685 Smooth merger; benefits to accrue HOLD KMB s consolidated PAT for Q4FY15 stood at INR 9.5 that primarily on the back of
More informationFederal Bank (FEDBAN) 50
Result Update Rating matrix Rating : Sell Target : 45 Target Period : 12 months Potential Upside : -10% What s Changed? Target Changed from 60 to 45 EPS Changed from 4.7 to 4.0 EPS Changed from 5.4 to
More informationPTC India Financial Services (PTCIND) 42
Result Update Rating matrix Rating : Buy Target : 51 Target Period : 12 months Potential Upside : 25% What s Changed? Target Changed from 55 to 51 EPS FY16E Changed from 7.6 to 6.6 EPS FY17E Changed from
More informationPI Industries. 2QFY16 Result Review HOLD. Custom synthesis restricted 2Q revenue growth ; maintain HOLD. Sector: AGRI
$Com panyname$ Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) HOLD PI Industries Ltd. Custom synthesis
More informationCoal India Ltd. Subdued e-auction realization impacted profitability BUY. Nov. 17, 2015
17-Nov-14 17-Dec-14 17-Jan-15 17-Feb-15 17-Mar-15 17-Apr-15 17-May-15 17-Jun-15 17-Jul-15 17-Aug-15 17-Sep-15 17-Oct-15 Coal India Ltd. Subdued e-auction realization impacted profitability Coal India Ltd.
More informationHow To Value Powergrid (India)
Result Update Rating matrix Rating : Hold Target : 68 Target Period : 12 months Potential Upside : 9% What s Changed? Target Changed from 72 to 68 EPS FY16E Changed from 6.4 to 6.5 EPS FY17E Changed from
More informationStrong operational performance
ABB India Equity Research Engineering & Capital Goods February 8, 2016 Result Update Emkay Your success is our success Strong operational performance CMP Target Price Rs1,134 Rs1,407 ( ) Rating Upside
More informationGail (India) Ltd (GAIL) 305
Result Update Rating matrix Rating : Buy Target : 355 Target Period : 18-24 months Potential Upside : 16% What s changed? Target Changed from 390 to 355 EPS FY16E Changed from 17.2 to 14.2 EPS FY17E Changed
More informationGlaxoSmithKline Consumer Healthcare
Strong pricing power, Attractive valuations "BUY" February 09, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs5,837
More informationSUPREME INDUSTRIES LTD Plastic Products HOLD RETAIL EQUITY RESEARCH
Q2FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH SUPREME INDUSTRIES LTD Plastic Products BSE CODE:509930 NSE CODE: SUPREMEIND Bloomberg CODE: SIL IN SENSEX: 24,470 HOLD CMP Rs725
More informationSimplex Infrastructures
2QFY216 Result Update Infrastructure November 17, 215 Simplex Infrastructures Performance Highlights Quarterly highlights - Standalone Y/E March (` cr) 2QFY16 1QFY16 2QFY15 % chg (yoy) % chg (qoq) Net
More informationNavin Fluorine International
RESULTS REVIEW 2QFY16 29 OCT 2015 Navin Fluorine International INDUSTRY CHEMICALS CMP (as on 29 Oct 2015) Rs 1,579 Target Price Rs 1,800 Nifty 8,112 Sensex 26,838 KEY STOCK DATA Bloomberg NFIL IN No. of
More informationBUY. Muted Q3; Brands & Retail story to unfold ARVIND. Target Price: Rs 344. Segmental highlights
05 FEB 2016 Quarterly Update BUY Target Price: Rs 344 Muted Q3; Brands & Retail story to unfold Arvind s Q3 consolidated revenue at Rs 21.6 bn (Rs 20.7 bn in Q3FY15) was marginally below our estimate of
More informationThe Ramco Cements. Source: Company Data; PL Research
Robust performance; remains the best play on Southern region February 09, 2016 Kamlesh Bagmar kamleshbagmar@plindia.com +91 22 66322237 Ankit Shah ankitshah@plindia.com +91 22 66322244 Rating BUY Price
More informationMaruti Suzuki. Source: Company Data; PL Research
Q3 results subdued, Outlook remains good; BUY January 28, 2016 Rohan Korde rohankorde@plindia.com +91 22 66322235 Rating BUY Price Rs4,103 Target Price Rs4,844 Implied Upside 18.1% Sensex 24,470 Nifty
More informationCoal India (COALIN) 307
Result Update June 2, 2016 Rating matrix Rating : Buy Target : 350 Target Period : 12 months Potential Upside : 14% What's Changed? Target Changed from 375 to 350 EPS FY17E Changed from 25.7 to 24.5 EPS
More informationMahanagar Gas Ltd. Attractively priced issue. IPO Review. Price band 380-421. ICICI Securities Ltd Retail Equity Research
IPO Review Rating matrix Rating : Subscribe Issue Details Issue Opens 21-Jun-16 Issue Closes 23-Jun-16 Issue Size ( Crore) 940-1040 Price Band ( ) 380-421 No of Shares on Offer (Crore) 2.47 QIB (%) 50
More informationNatco Pharma (NATPHA) 961
Company Update Rating matrix Rating : Hold Target : 14 Target Period : 12 months Potential Upside : 8% What s Changed? Target Changed from 8 to 14 EPS FY15E Changed from 35.6 to 37.9 EPS FY16E Changed
More informationJSW Energy Ltd. Interest expenses dragged the bottom-line BUY. Jan. 25, 2016
JSW Energy Ltd. Interest expenses dragged the bottom-line JSW Energy Ltd. (JSWEL) reported a mixed set of numbers for Q3 FY16 quarter. The company reported a consolidated total operating income of Rs.
More informationHathway Cable & Datacom (HATCAB) 40
Result Update Rating matrix Rating : S ell Target : 36 Target Period : 12 months Potential Upside : - 10% What s changed? Target Changed from 42 to 36 EPS FY16E Changed from -2.1 to -2.1 EPS FY17E Changed
More informationTree House Education & Accessories
2QFY2016 Result Update Educational Services November 10, 2015 Tree House Education & Accessories Performance Highlights Y/E March (` cr) 2QFY16 2QFY15 % chg (qoq) 1QFY16 % chg (yoy) Net sales 57 50 15.1
More informationMphasis. FY17 could be a year of revenue growth. Source: Company Data; PL Research
FY17 could be a year of revenue growth February 08, 2016 Govind Agarwal govindagarwal@plindia.com +91 22 66322300 Rating Accumulate Price Rs440 Target Price Rs510 Implied Upside 15.9% Sensex 24,617 Nifty
More informationHindalco Industries (HINDAL) 82
Result Update Rating matrix Rating : Hold Target : 75 Target Period : 12 months Potential Upside : -8% What s Changed? Target Changed from 85 to 75 EPS FY16E Changed from 3.4 to 3.5 EPS FY17E Changed from
More informationJust Dial Ltd Bloomberg Code: JUST IN
Communications - Internet Media Oct 14, 215 Bloomberg Code: JUST IN India Research - Stock Broking India s local search engine, warming up with add-on services Just Dial is now into a platform where people
More informationBata India Ltd. (BIL)
Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Q2FY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Bata India Ltd. (BIL) Cloudy quarter sunshine ahead;
More informationBritannia Industries
Rally in Input costs near term drag, Maintain BUY June 20, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating BUY Price Rs2,641
More informationVRL Logistics. IPO Review. Price band 195 205. ICICI Securities Ltd Retail Equity Research
IPO Review Rating matrix Rating : Unrated Issue Details Issue opens 15-Apr-15 Issue closes 17-Apr-15 Issue size ( crore) 451-468 No of shares on offer (crore) 2.28 Fresh Issue 0.58 PE Exit 1.70 QIB 50%
More informationAccumulate. Exide Industries Ltd(EIL) Automobile Ancillaries RETAIL EQUITY RESEARCH
Q3FY16 RESULT UPDATE GEOJIT BNP PARIBAS Research RETAIL EQUITY RESEARCH Exide Industries Ltd(EIL) Automobile Ancillaries BSE CODE: 500086 NSE CODE: EXIDEIND Bloomberg CODE: EXID IN SENSEX: 23,759 Accumulate
More informationHow To Value Hpl In India
Materials - Containers & Packaging Oct 01, 2015 Bloomberg Code: HPPL IN India Research - Stock Broking Backed by Acquisition, Set to Augment Market Share New acquisition: In FY15, HPPL acquired 100% of
More informationQuess Corp Ltd. IPO Review. Price band 310-317. ICICI Securities Ltd Retail Equity Research. Investment Rationale Staffing industry at nascent stage
IPO Review Rating matrix Rating : Unrated Issue Details Issue Opens Issue Closes 29-Jun-16 1-Jul-16 Issue Size ( Crore) 400 Price Band ( ) 310-317 No of Shares on Offer (crore) 1.29-1.26 QIB (%) 75 Non-Institutional
More informationCity Union Bank (CITUNI) 87
Result Update October 3, 215 Rating matrix Rating : Buy Target : 15 Target Period : 12 months Potential Upside : 2% What s Changed? Target Changed from 114 to 15 EPS FY16E Changed from 7.8 to 7.1 EPS FY17E
More informationSalzer Electronics. 2QFY16 Result Review BUY. Steady performance continued; maintain BUY. Sector: Electric Equipment
$CompanyN ame$ Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 2QFY16 Result Review (Wholly owned subsidiary of Bank of Baroda) BUY Salzer Electronics Ltd. Steady
More informationCredit Analysis & Research (CARE) 1310
Result Update Rating matrix Rating : Buy Target : 17 Target Period : 12 months Potential Upside : 3% What s changed? Target Changed from 2 to 17 EPS FY16E Changed from 46.1 to 45.9 EPS FY17E Changed from
More informationBUY. ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16. CMP 1677.00 Target Price 1880.00. SEPTEMBER 2 nd, 2015 SYNOPSIS ISIN: INE738I01010
BUY CMP 1677.00 Target Price 1880.00 ECLERX SERVICES LIMITED (CONSOLIDATED) Result Update: Q1 FY16 SEPTEMBER 2 nd, 2015 ISIN: INE738I01010 Index Details Stock Data Sector IT & ITes BSE Code 532927 Face
More informationGranules India Ltd. INR 113
India Equity Institutional Research Pharma RESULT UPDATE Granules India Ltd. INR 113 Misses expectation BUY Result highlights Net sales for the quarter grew by a moderate 8% YoY to INR 3,449mn below our
More informationHOLD. The case of missing sales growth ZYDUS WELLNESS. Target Price: Rs 780. Q3highlights
The case of missing sales growth Zydus Q3 net sales at Rs1.1 bn was up 3% on a like-to-like basis (Q3 15 had Rs 223 mn additional excise duty credit from prior periods), below our estimate of 6%. The company
More informationTechno Electric & Engineering Limited
Engineering & Capital Goods Event Update Techno Electric & Engineering Limited Buy Wind business spin off will lead to value unlocking. Institutional Research CMP (`) 404 Target (`) 504 Nifty: 8,224 Sensex:
More informationResults impacted by subdued demand
India Equity Research Agri Input & Chemicals January 25, 2016 Result Update Coromandel International Results impacted by subdued demand Emkay Your success is our success CMP Target Price Rs165 Rs225 (
More informationHOLD. Q4 earnings beat but order backlog flat ABB. Target Price: Rs 1,213. Key drivers
05 FEB 2016 Quarterly Update HOLD Target Price: Rs 1,213 Q4 earnings beat but order backlog flat s Q4CY15revenue at Rs24bnwasin line withour expectation of Rs24bn. EBITDA margin improved 290 bps YoYand
More informationHathway Cable & Datacom (HATCAB) 36
Result Update Rating matrix Rating : S ell Target : 32 Target Period : 12 months Potential Upside : - 12% What s changed? Target Changed from 36 to 32 EPS FY16E Changed from -2.1 to -2.2 EPS FY17E Changed
More informationOrchid Chemicals NEUTRAL. Performance Highlights. Target Price - 1QFY2011 Result Update Pharmaceutical. Investment Period -
1QFY211 Result Update Pharmaceutical July 21, 21 Orchid Chemicals Performance Highlights Y/E March (Rs cr) 1QFY211 4QFY21 %chg (qoq) 1QFY21 %chg (yoy) Net Sales 34 286 6.3 36 (.7) Other Operating Income
More informationBUY. KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16. CMP 226.50 Target Price 260.00. JANUARY 9 th 2015 SYNOPSIS ISIN: INE164B01022
BUY CMP 226.50 Target Price 260.00 KELLTON TECH SOLUTIONS LTD Result Update (CONSOLIDATED): Q1 FY16 JANUARY 9 th 2015 ISIN: INE164B01022 Index Details Stock Data Sector IT Software Products BSE Code 519602
More informationBDI BioEnergy Intern. 20.0 Neutral. Activity level in Q3 might not support FY estimates
8/11/1 8/1/11 8/3/11 8/5/11 8/7/11 8/9/11 8/11/11 8/1/12 8/3/12 8/5/12 8/7/12 8/9/12 MATELAN Research Preview Note Price as of 9/11/12: 8.69 12 November 212 Company / Sector Fair Value Recommendation BDI
More informationPidilite Industries. Source: Company Data; PL Research
Bountiful margin expansion in a tepid demand scenario February 03, 2016 Amnish Aggarwal amnishaggarwal@plindia.com +91 22 66322233 Gaurav Jogani gauravjogani@plindia.com +91 22 66322238 Rating Accumulate
More informationHow To Understand And Value Gsk Pharma
2QFY2016 Result Update Pharmaceutical November 2, 2015 GlaxoSmithKline Pharma Performance Highlights Y/E Mar (` cr) 2QFY2016 1QFY2016 % chg (qoq) 2QFY2015 % chg (yoy) Net Sales 692 622 11.3 739 (6.4) Other
More informationEmkay. Revenues traction improves; Retain BUY HSIL. Healthy revenue performance; miss on margins
HSIL India Equity Research Others February 3, 2016 Result Update Emkay Your success is our success Revenues traction improves; Retain BUY CMP Target Price Rs271 Rs370 ( ) Rating Upside BUY ( ) 36.6 % Healthy
More informationIndia Equity Research Telecommunications September 2, 2015 Management Meet Update
Bharti Infratel India Equity Research Telecommunications September 2, 2015 Management Meet Update Emkay Your success is our success Data demand to accelerate growth CMP Rs396 Target Price Rs505 ( ) Rating
More informationShare gains with healthy margin uptick; Retain Buy
Colgate-Palmolive India Equity Research Consumers January 23, 2015 Result Update Emkay Your success is our success Share gains with healthy margin uptick; Retain Buy CMP Target Price Rs1,913 Rs1,940 (
More informationCipla Ltd. Rs. 741. India Equity Institutional Research Pharma. One off revenues from Nexium supply drives earnings HOLD. Target Price (Rs): 765
India Equity Institutional Research Pharma RESULT UPDATE Cipla Ltd. Rs. 741 One off revenues from Nexium supply drives earnings HOLD Result highlights Cipla s Q1FY16 result beats our estimates due to higher
More informationLarsen & Toubro. Source: Company Data; PL Research
Order inflow surprise, challenges on profitability continues! January 29, 2016 Kunal Sheth kunalsheth@plindia.com +91 22 66322257 Samir Bendre samirbendre@plindia.com +91 22 66322256 Rating BUY Price Rs1,102
More informationIn line performance. Results update 4Q2015. Banks UAE 28 January 2016 DUBAI ISLAMIC BANK
28 Jan 15 28 Apr 15 28 Jul 15 28 Oct 15 DUBAI ISLAMIC BANK In line performance Results update 4Q2015 Banks UAE 28 January 2016 Dubai Islamic Bank s (DIB) reported net profit of AED865mn, in-line with our
More informationBUY. Key Risks. Technology - Technology Services - Information Services. Nov 19, 2015. CRISIL Ltd. Recommendation (Rs.)
Technology - Technology Services - Information Services India Research - Stock Broking Economic recovery to boost revenues across business segments: The rating revenues witnessed 8% growth in 214 compared
More informationMangalam Cement Weak volumes marred performance
CMP* (Rs) 206 Market Cap. (Rs bn) 5.5 Free Float (%) 72 Shares O/S (mn) 26.7 Mangalam Cement Weak volumes marred performance Mangalam Cement (MCL) delivered a weak performance in 2Q but was marginally
More informationApollo Tyres (APOTYR) 169
Result Update Rating matrix Rating : Buy Target : 240 Target Period : 12 months Potential Upside : 42% What s Changed? Target Changed from 260 to 240 EPS FY15E Changed from 22.1 to 20.5 EPS FY16E Changed
More informationGreenply Industries Ltd
Change in Estimates Rating Target Greenply Industries Ltd Q2 FY16 Q2FY16 net revenue of Greenply Industries or GIL at Rs401cr, 2.5%/9.2% below our/bloomberg estimate of Rs411cr/Rs441cr, respectively, led
More informationBUY RSWM LTD SYNOPSIS. CMP 292.20 Target Price 336.00. SEPTEMBER 1 st 2015. Result Update(PARENT BASIS): Q1 FY16
BUY CMP 292.20 Target Price 336.00 RSWM LTD Result Update(PARENT BASIS): Q1 FY16 SEPTEMBER 1 st 2015 ISIN: INE611A01016 Index Details Stock Data Sector Textiles BSE Code 500350 Face Value 10.00 52wk. High
More informationPrivate drilling fluid technology service leader
21 March 2012 Equity Research Report Company Research Petroleum & Petrochemical Sichuan Renzhi Oilfield Technology Services (002629) Investment value analysis report Private drilling fluid technology service
More informationHOLD HEXAWARE TECHNOLOGIES. Q4 lackluster; CY16 holds promise. Target Price: Rs 252. Q4earnings concall highlights
05 FEB 2016 Quarterly Update HOLD Target Price: Rs 252 Q4 lackluster; CY16 holds promise Hexaware s Q4CY15 performance was lower than our estimates. Revenue growth and margin were largely impacted due
More informationSmruthi Organics Limited BSE Scrip Code: 590046
Smruthi Organics Limited BSE Scrip Code: 590046 Pharmaceuticals September 21, 2012 Equity Statistics Current Market Price Rs. 218.1 52 Week High / Low Rs. 273.9 / 155 Market Capitalisation Rs. crores 83.2
More informationApollo Tyres (APOTYR) 170
Result Update Rating matrix Rating : Buy Target : 200 Target Period : 12 months Potential Upside : 18% What s Changed? Target Changed from 228 to 200 EPS FY16E Changed from 21.2 to 20.6 EPS FY17E Changed
More informationJubilant Life Sciences
Radiopharma, Niacin continues to drive sales, margins October 30, 2015 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs401 Target Price Rs578 Implied Upside 44.1% Sensex 26,838 Nifty
More informationSphere Global Services Limited
Sphere Global Services Limited Date: 13 th January, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 3.95^ Face Value : ` 1 per share 52 wk High / Low : ` 9.35 / 31.1
More informationAxis Bank. Strong core performance. Source: Company Data; PL Research
Strong core performance January 17, 2011 Abhijit Majumder abhijitmajumder@plindia.com +91 22 66322236 Umang Shah umangshah@plindia.com +91 22 66322242 Rating BUY Price Rs1,230 Target Price Rs1,600 Implied
More informationBUY GUJARAT STATE PETRONET. Operationally in line; other income surprises. Target Price: Rs 160. Valuations comfortable. Visible triggers ahead
05 FEB 2016 Quarterly Update BUY Target Price: Rs 160 Operationally in line; other income surprises GSPL s Q3FY16PAT at Rs 1.2bn was higher than our estimate (Rs 1.1bn) due to higher other income at Rs
More informationICICI BANK INR 233. Dismal asset quality performance. Target Price (INR): 314. India Equity Institutional Research BFSI.
India Equity Institutional Research BFSI RESULT UPDATE ICICI BANK INR 233 Dismal asset quality performance BUY Q3FY15 earnings for ICICI Bank came as a huge disappointment with bank reporting highest NPAs
More informationQ3 FY 2015 Earnings Update
Q3 FY 2015 Earnings Update 1 Safe Harbour No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the
More informationDATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015
BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price
More informationRAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS. Earnings Presentation Q2 FY16
RAJESH EXPORTS LIMITED GLOBAL PRESENCE IN GOLD AND GOLD PRODUCTS Earnings Presentation Q2 FY16 Company Overview COMPANY OVERVIEW Rajesh Exports Ltd. (REL) was incorporated in 1989. Currently REL is a leader
More informationRamKrishna Forgings Ltd.
January 3, 2014 RamKrishna Forgings Ltd. Poised for Growth CMP INR 81 Target INR 117.2 Coverage Follow Up BUY Key Share Data Face Value (INR) 10 Equity Capital (in INR Million) 211.0 Market Cap (in INR
More information